During Monday’s trade, Shares of DISH Network Corp (NASDAQ:DISH), lost -1.78% to $57.95.
DISH Network Corporation, declared a series of senior administration changes intended to fulfill the company’s planned aims and align its business to more fully respond to the dynamic pay-TV environment.
DISH veteran of 20 years and EVP of Operations, Erik Carlson, has been named President and Chief Operating Officer. Carlson will supervise all DISH revenue-generating, operating and administrative units, counting Customer Acquisition and Retention, Finance and Accounting, Human Resources, Marketing, Media Sales, Programming, Operations and DISH’s newly formed Technology Office.
Current DISH COO and EVP Bernie Han was named EVP of Planned Planning and will continue reporting to DISH Chairman and CEO Charlie Ergen, who is relinquishing the role of DISH President.
DISH Network Corporation, through its auxiliaries, provides pay TV services in the United States. The company operates through two segments, DISH and Wireless. The company provides video services under the DISH brand. It also offers programming packages that comprise regional and specialty sports channels, premium movie channels, and Latino and international programming through national broadcast networks, local broadcast networks, and national and regional cable networks; and receiver systems.
Shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP), declined -2.20% to $4.44, during its current trading session.
Raptor Pharmaceutical Corp., declared 36-month efficacy results from a Phase 2/3 clinical trial evaluating RP103 for the potential treatment of Huntington’s disease, called CYST-HD, conducted in partnership with the Centre Hospitalier Universitaire d’Angers (CHU d’Angers), France. Data from the study revealed that there was a slowing in the rate of change in the Total Motor Score (TMS) component of the Unified Huntington’s Disease Rating Scale (UHDRS) at 36 months of treatment favoring earlier RP103 treatment (RP103-RP103) as contrast to delayed start of RP103 treatment (placebo-RP103). The 25% treatment effect in TMS favoring subjects treated with RP103 for the full 36 months as contrast to the placebo/RP103 arm, while not statistically significant, is regarded by clinical leaders in the field as clinically meaningful. The TMS data were consistent with observed effects in key functional measures counting Total Functional Capacity (TFC) and Independence Scale. There was statistically noteworthy improvement in the Independence Scale.
Huntington’s disease is a rare, inherited, neurodegenerative disorder that causes motor, cognitive and behavioral dysfunction, deterioration and premature death. There is no presently approved drug that slows disease progression.
“The 36-month efficacy results from the CYST-HD study are clinically meaningful and suggest that RP103 may play an important role in the treatment of Huntington’s disease,” said Dominique Bonneau, M.D., Professor of Medical Genetics at the CHU d’Angers and principal investigator for CYST-HD. “These data warrant further assessment as there remains a clear need for new, safe and tolerable therapies to treat this disease.”
Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The company offers PROCYSBI, a delayed-release capsule, which is used for the administration of nephropathic cystinosis in adults, in addition to in six years and older children in the United States, in the 28 member states of the European Union, Norway, Liechtenstein, and Iceland. Its clinical development programs comprise RP103 that is used as a treatment for Huntington’s disease; RP103 as a treatment for non-alcoholic fatty liver disease in children; and RP103 as a treatment for mitochondrial disorders, counting Leigh syndrome.
Finally, Mobil’nye Telesistemy PAO (ADR) (NYSE:MBT), gained 0.08%, and is now trading at $6.38.
Bell Integrator is a global consulting, technology services and IT outsourcing company delivering mission critical solutions that address most complex business and technology needs of large corporations in the finance, telecom, transportation and healthcare industries. Customers comprise carriers, such as VimpelCom (VIP), MTS (MBT), MegaFon (LSE:MFON) and Rostelecom (ROSYY), serving over 600m subscribers daily, top-tier global banks, counting Citibank, Deutsche Bank, Raiffeisen Bank, Societe Generale and others with average capitalization of over $10bn, large transportation and healthcare enterprises.
Bell Integrator, declared that it has been listed by Software Magazine among its Software 500, a ranking of the world’s 500 largest software and services suppliers, now in its 33rd year. Based on 2014 Software/Software Services revenue, Bell Integrator’s rank is 228, reporting a 12% improvement from prior year data.
The Software 500 is a revenue-based ranking of the world’s largest software and services suppliers, targeting medium to large enterprises, their IT professionals, software developers, and business managers involved in software and services purchasing.
“We are extremely proud to be listed among the 500 Largest Software Companies in the world,” said Eugene Pozdnikov, Managing Director, Bell Integrator USA. “This achievement is further validation of our company’s success in providing high quality software solutions to our customers.”
Mobile Tele Systems PJSC provides telecommunication services in Russia and the Commonwealth of Independent States. It offers a range of mobile and fixed line voice and data telecommunications services, counting data transfer, broadband, pay-TV, and various value-added services, in addition to sells equipment and accessories.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.